Focused On-demand Library for Sialomucin core protein 24

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Endolyn; Multi-glycosylated core protein 24

Alternative UPACC:

Q04900; B4DQ85; E1P5E7; E1P5E8; E1P5E9; O95413; Q5JSU6; Q9BPV0; Q9NR26


Sialomucin core protein 24, also known as Endolyn or Multi-glycosylated core protein 24, plays a pivotal role in various biological processes. It is instrumental in hematopoiesis, facilitating the adhesion of CD34(+) cells to the stroma and modulating their proliferation. Additionally, it influences the migration of umbilical cord blood CD133+ cells through the CXCL12/CXCR4 axis, and is implicated in prostate cancer metastasis and myogenesis by enhancing cell motility and promoting myoblast fusion into myotubes.

Therapeutic significance:

The association of Sialomucin core protein 24 with autosomal dominant deafness, 66, underscores its potential as a target for therapeutic intervention. Understanding the role of Sialomucin core protein 24 could open doors to potential therapeutic strategies, particularly in the treatment of sensorineural hearing loss and possibly in cancer metastasis and muscle regeneration.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.